Off label use of lithium in the treatment of Huntington's disease: A case series

Indian Journal of Psychiatry

Volumn 55, Issue 1, 2013, Pages 81-83

  Danivas, Vijay ^a   Moily, Nagaraj ^a   Thimmaiah, Rohini ^a   Muralidharan, Kesavan ^a   Purushotham, Meera ^a   Muthane, Uday ^b   Jain, Sanjeev ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b Parkinson's and Ageing Research Foundation   (India)

Author keywords

Huntington's disease; lithium; neuroprotection

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; HUNTINGTIN; LITHIUM; QUETIAPINE;

ADULT; AGGRESSION; ARTICLE; BEHAVIOR CHANGE; CAG REPEAT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FAMILY HISTORY; FEMALE; FOLLOW UP; GENETIC ANALYSIS; HUMAN; HUNTINGTON CHOREA; IRRITABILITY; LOW DRUG DOSE; MALE; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OFF LABEL DRUG USE; PERSECUTORY DELUSION; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84873451118     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.105522     Document Type: Article

References (17)

1. Moily NS, Purushottam M, Pal PK, Jain S. Huntington's disease. In: Sinha KK, Jha DK, editors. Monograph on Movement Disorders. The association of physicians of India: Indian College of Physicians: 2012. p. 213-34.
2. Kanazawa I. Therapeutic strategies in Huntington's disease. J Clin Neurol 2006;2:213-24.
3. Pérez-Martínez DA. The role of lithium in neurodegenerative diseases: New registries for old actors. Neurologia 2009;24:143-6.
4. Kumar P, Kalonia H, Kumar A. Huntington's disease: Pathogenesis to animal models. Pharmacol Rep 2010;62:1-14.
5. Chuang DM, Chen RW, Chalecka-Franaszek E, Ren M, Hashimoto R, Senatorov V, et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002;4:129-36.
6. Aghdam SY, Barger SW. Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: Lessons from lithium. Curr Alzheimer Res 2007;4:21-31.
7. Camins A, Verdaguer E, Junyent F, Yeste-Velasco M, Pelegrí C, Vilaplana J, et al. Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosci Ther 2009;15:333-44.
8. Jope RS. Lithium and GSK-3: One inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003;24:441-3.
9. Young W. Review of lithium effects on brain and blood. Cell Transplant 2009;18:951-75.
10. Machado-Vieira R, Manji HK, Zarate CA. The role of lithium in the treatment of bipolar disorder: Convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 2009;11:92-109.
11. Chuang DM. The antiapoptotic actions of mood stabilizers: Molecular mechanisms and therapeutic potentials. Ann N Y Acad Sci 2005;1053:195-204.
12. Wada A. Lithium and neuropsychiatric therapeutics: Neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol Sci 2009;110:14-28.
13. Nonaka S, Hough CJ, Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 1998;95:2642-7.
14. Sarkar S, Rubinsztein DC. Inositol and IP3 levels regulate autophagy: Biology and therapeutic speculations. Autophagy 2006;2:132-4.
15. Boku S, Nakagawa S, Masuda T, Nishikawa H, Kato A, Kitaichi Y, et al. Glucocorticoids and lithium reciprocally regulate the proliferation of adult dentate gyrus-derived neural precursor cells through GSK-3beta and beta-catenin/TCF pathway. Neuropsychopharmacology 2009;34:805-15.
16. Wexler EM, Geschwind DH, Palmer TD. Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol Psychiatry 2008;13:285-92.
17. Tsai LK, Leng Y, Wang Z, Leeds P, Chuang DM. The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms. Neuropsychopharmacology 2010;35:2225-37.